Ariel I M, Briceno M
J Surg Oncol. 1975;7(4):269-87. doi: 10.1002/jso.2930070403.
This report details the clinical experience of 150 patients with rhabdomyosarcomas treated by one group of surgeons. Of the 150 patients, 103 suffered from pleomorphic rhabdomyosarcomas, 40 patients had embryonal rhabdomyosarcomas, and 7 had alveolar cell type of rhabdomyosarcoma. The males suffered almost twice as much as the females from this form of cancer (96 males to 54 females). The fifth decade had the highest incidence of all rhabdomyosarcomas. The younger patients generally suffered from embryonal rhabdomyosarcomas and the older ones from pleomorphic rhabdomyosarcomas, although age was no barrier to the occurrence of embryonal rhabdomyosarcomas in some of the older patients and pleomorphic rhabdomyosarcomas in some of the younger patients. Caucasians were almost exclusively afflicted by this form of cancer (93% of this series). The lower extremity was the most frequent site of the lesion, occurring in 50.7% of the 150 cases. The upper extremity was the second most frequently involved site (28%), and the trunk was the least involved site (21.3%). Of the 150 patients studied, 40 were considered indeterminate. Thirteen patients are alive and free of cancer, but were treated less than 5 years ago; 12 patients reported for consultation only. There were 13 who were free of sarcomas at periods in excess of 2 years but were lost to follow-up. Two patients in this series died before the 5-year period, and autopsy revealed the death to be due to causes other than the rhabdomyosarcoma. Of the 110 determinate patients, 75 (68%) died as a result of the cancer. The 5-year survival rate equals 32%. The fact of the 30% 5-year survival after treatment for recurrences should help dismiss the pessimism which prevails once a recurrence is noted subsequent to major therapy. Age per se had no great effect on prognosis. The poorest results occurred in the 11-20 age range, with a 5-year survival of 15%. This value reflects on increased incidence of embryonal rhabdomyosarcomas which tend to be more malignant and metastasize earlier than do the pleomorphic type. The effect of location upon survival revealed that of 76 patients with involvement of the lower extremity, 34% survived 5 years or longer, and those with sarcomas of the trunk had the poorest survival (26%). The fact that the trunk, by virtue of its anatomy, limits the degree of surgery that can be perfomred, probably helps to explain this difference. The role of radiation therapy and chemotherapy awaits elucidation. Reports of combined surgery, radiation therapy, and chemotherapy are encouraging.
本报告详细介绍了一组外科医生治疗的150例横纹肌肉瘤患者的临床经验。在这150例患者中,103例患有多形性横纹肌肉瘤,40例患有胚胎性横纹肌肉瘤,7例患有肺泡细胞型横纹肌肉瘤。患这种癌症的男性人数几乎是女性的两倍(男性96例,女性54例)。所有横纹肌肉瘤在第五个十年发病率最高。年轻患者一般患胚胎性横纹肌肉瘤,年长患者患多形性横纹肌肉瘤,不过年龄并非一些老年患者发生胚胎性横纹肌肉瘤以及一些年轻患者发生多形性横纹肌肉瘤的障碍。几乎只有白种人患这种癌症(本系列病例的93%)。下肢是最常见的病变部位,在150例病例中有50.7%发生于此。上肢是第二个最常受累的部位(28%),躯干是受累最少的部位(21.3%)。在研究的150例患者中,40例情况不明。13例患者存活且无癌症,但治疗时间不到5年;12例仅前来咨询。有13例在超过2年的时间里无肉瘤,但失去了随访。本系列中有2例患者在5年之前死亡,尸检显示死亡原因并非横纹肌肉瘤。在110例明确诊断的患者中,75例(68%)死于癌症。5年生存率为32%。复发治疗后5年生存率达30%这一事实应有助于消除在主要治疗后出现复发时普遍存在的悲观情绪。年龄本身对预后影响不大。最差的结果出现在11至20岁年龄组,5年生存率为15%。这一数值反映出胚胎性横纹肌肉瘤发病率增加,这类肿瘤往往比多形性类型更具恶性且转移更早。病变部位对生存的影响显示,76例下肢受累患者中,34%存活5年或更长时间,而躯干肉瘤患者的生存率最差(26%)。由于躯干的解剖结构限制了所能进行的手术程度,这一事实可能有助于解释这种差异。放射治疗和化疗的作用有待阐明。关于手术、放射治疗和化疗联合应用的报告令人鼓舞。